Related Experiment Video
Updated: Jun 15, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Aldosterone: effects on the kidney and cardiovascular system
Marie Briet1, Ernesto L Schiffrin
1Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital and Lady Davis Institute for Medical Research, McGill University, 3755 Côte-Ste-Catherine Road, Montreal, QC H3T 1E2, Canada.
Nature Reviews. Nephrology
|March 18, 2010
Summary
Aldosterone impacts kidneys and heart, especially with high salt intake. Mineralocorticoid receptor antagonists benefit heart failure patients and show promise for chronic kidney disease.
Area of Science:
- Endocrinology
- Nephrology
- Cardiology
Background:
- Aldosterone regulates sodium reabsorption via epithelial sodium channels (ENaC) in the kidney.
- Beyond renal effects, aldosterone influences the cardiovascular system, contributing to hypertrophy and fibrosis.
- Its detrimental effects are exacerbated by high salt intake, oxidative stress, and inflammation.
Purpose of the Study:
- To review the multifaceted roles of aldosterone in kidney and cardiovascular diseases.
- To highlight the therapeutic potential of mineralocorticoid receptor antagonists.
Main Methods:
- Literature review of aldosterone's actions and clinical trial data.
- Analysis of aldosterone's effects on renal and cardiovascular tissues.
- Evaluation of mineralocorticoid receptor antagonist efficacy in heart failure and chronic kidney disease.
Main Results:
- Aldosterone contributes to renal inflammation, fibrosis, podocyte injury, and mesangial cell proliferation.
- Cardiovascular effects include hypertrophy, fibrosis, and endothelial dysfunction.
- Mineralocorticoid receptor antagonists improve outcomes in heart failure and reduce proteinuria in chronic kidney disease.
Conclusions:
- Aldosterone plays a significant role in the pathophysiology of kidney and cardiovascular diseases.
- Mineralocorticoid receptor antagonists are beneficial in heart failure and show promise in chronic kidney disease, warranting further large-scale trials.
Related Concept Videos
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...